Treats infections caused by susceptible strains of the designated microorganisms in the…. ANDA 65447, held by Epic Pharma. Demeclocycline Hydrochloride.
As of Nov 21, 2026, ANDA 65447 (Demeclocycline Hydrochloride), held by Epic Pharma, was first approved by FDA on Aug 18, 2015, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Demeclocycline hydrochloride tablets USP is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae; Lymphogranuloma venereum due to Chlamydia trachomatis; Psittacosis (Ornithosis) due to Chlamydia psittaci; Trachoma due to Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by Chlamydia trachomatis; Nongonococcal urethri…
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 18, 2015 | Original application | Approved |
| Demeclocycline Hydrochloride150MG · tablet;oral | Demeclocycline Hydrochloride | Rx |
| Demeclocycline Hydrochloride300MG · tablet;oral | Demeclocycline Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters